Hub : Traits :

Tanning

1987 significantly associated models · 322 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	62552269	64021096	1	1	6.6e-14	3.5e-24	1.3e-12	51	ATG4C
2	1	65294331	67944069	4	4	8.1e-23	9.6e-57	3.9e-22	63	LEPR PDE4B SGIP1
3	1	119761038	120687115	2	1	5.9e-09	7.8e-12	2.7e-04	72	RP5-1042I8.7
4	1	149854324	151846517	16	8	6.9e-20	2.4e-20	1.0e+00	100	ANXA9 ARNT CTSS HORMAD1 RP11-316M1.12 RP11-54A4.2
5	1	154282146	156450740	19	2	3.9e-18	3.7e-18	1.0e+00	100	MTX1P1 ZBTB7B
6	1	204358667	205921859	5	1	1.2e-27	2.0e-38	7.2e-14	67	RBBP5
7	1	211765485	213229337	1	1	1.4e-08	9.0e-09	1.0e+00	100	PPP2R5A
8	2	24348096	26088769	5	2	6.0e-15	3.3e-15	2.6e-01	98	DNAJC27 POMC
9	2	26883355	28402863	7	1	4.2e-11	4.1e-14	5.3e-05	71	FNDC4
10	2	37453629	39300259	6	8	1.6e-30	1.8e-43	NaN	NaN	ATL2 CYP1B1 FAM82A1 RMDN2
11	2	62211083	63968655	1	1	8.8e-09	1.5e-06	4.3e-01	97	EHBP1
12	2	171683107	173114238	1	2	1.5e-13	3.4e-16	2.3e-01	98	CYBRD1
13	3	51860817	53573517	6	1	2.5e-08	1.1e-07	4.6e-01	98	RP5-966M1.6
14	3	84317575	86808226	1	1	1.2e-21	6.8e-25	1.0e-04	86	CADM2
15	3	97736804	99315838	3	1	9.0e-10	4.0e-10	1.2e-02	84	ST3GAL6-AS1
16	3	155544380	157226796	6	12	5.4e-18	5.0e-29	NaN	NaN	LEKR1 LINC00886 LOC100287227 METTL15P1 RP11-305K5.1 SSR3
17	5	12225	1214264	2	1	8.3e-11	1.8e-05	5.7e-01	98	CTD-2228K2.7
18	5	33241655	34706321	2	3	9.7e-35	0.0e+00	0.0e+00	11	AMACR RXFP3
19	5	59474215	61145102	2	2	3.6e-10	5.4e-11	3.0e-05	60	ERCC8 NDUFAF2
20	5	138753725	140337279	2	1	2.7e-08	1.5e-06	2.2e-01	94	LINC01024
21	5	176040488	177260129	2	1	7.9e-11	4.2e-10	7.2e-01	100	PRELID1
22	6	202452	1408677	3	12	3.3e-193	0.0e+00	NaN	NaN	EXOC2 RP11-532F6.3
23	6	35397127	36804187	1	1	1.4e-07	1.5e-08	2.7e-04	59	MAPK13
24	6	41073638	42587818	2	1	6.6e-12	5.6e-12	1.0e+00	100	MED20
25	6	51665597	53131343	1	1	2.5e-08	1.2e-08	1.8e-02	83	TRAM2
26	6	81504236	83161854	1	1	3.0e-07	1.4e-06	7.1e-05	32	FAM46A
27	6	145125929	146983441	5	1	2.4e-10	9.5e-12	9.8e-03	86	EPM2A
28	7	16622785	18084843	2	1	1.9e-10	1.1e-29	9.4e-28	7	AHR
29	7	27623776	28468319	1	1	5.0e-18	1.0e-19	7.8e-04	86	JAZF1
30	7	104060000	105736971	1	1	2.7e-07	1.3e-07	5.6e-07	10	SRPK2
31	8	41318439	42727452	1	1	7.5e-08	2.1e-07	1.4e-01	92	AP3M2
32	8	115726164	117519662	1	2	3.3e-40	1.6e-98	1.5e-54	46	TRPS1
33	8	144294773	145744618	2	1	2.2e-09	7.5e-08	3.1e-01	96	PARP10
34	9	11988659	13977570	4	7	9.2e-63	3.0e-81	NaN	NaN	C9orf150 LURAP1L MPDZ TYRP1
35	9	15714465	18201083	2	6	1.1e-54	1.7e-232	4.9e-125	47	BNC2 CNTLN
36	9	26851195	28272794	1	1	3.5e-10	9.9e-10	9.1e-02	92	C9orf72
37	10	5039564	6576881	2	1	8.4e-14	9.5e-13	5.3e-01	99	GDI2
38	10	63856856	65606229	3	1	1.2e-13	1.7e-13	2.1e-02	90	NRBF2
39	10	101213253	102632622	1	1	2.1e-07	5.2e-11	4.1e-11	-1	ERLIN1
40	11	15288270	17459851	1	1	3.7e-11	9.6e-14	2.4e-04	76	SOX6
41	11	47193566	47695840	1	1	4.6e-08	3.1e-07	1.2e-01	91	PSMC3
42	11	67976812	69623641	4	7	5.6e-55	4.0e-49	NaN	NaN	IGHMBP2 RP11-554A11.9 TPCN2
43	11	77027574	78828001	4	1	1.6e-10	3.1e-11	2.9e-02	89	USP35
44	11	87146898	90616949	5	12	1.2e-38	0.0e+00	0.0e+00	17	CTSC NAALAD2 NOX4 RAB38
45	12	40388337	42165804	1	1	1.1e-09	7.6e-10	1.0e+00	100	CNTN1
46	12	55933641	57318731	2	2	1.4e-08	1.0e-06	8.0e-01	100	OBFC2B SILV
47	12	87841866	89262140	1	3	1.1e-35	1.2e-38	1.3e-03	94	TMTC3
48	12	124700826	126101198	1	1	1.9e-09	1.3e-14	7.0e-07	59	UBC
49	13	94398894	95827872	1	1	4.8e-18	3.7e-18	6.7e-02	96	DCT
50	13	113081675	114502416	1	1	9.8e-08	8.7e-72	1.3e-65	9	F10
51	14	77106456	78542305	1	1	1.7e-07	4.6e-05	4.2e-01	96	TMED8
52	14	91738696	93201999	1	1	1.7e-08	6.9e-55	4.7e-48	13	TRIP11
53	15	27302102	28535266	2	4	6.4e-283	8.1e-305	3.0e-80	74	HERC2 OCA2
54	16	4144898	4715012	1	1	2.3e-07	3.3e-07	1.0e+00	100	CORO7
55	16	13315655	14742400	1	1	2.2e-12	1.4e-15	2.0e-14	8	ERCC4
56	16	71070698	72838680	3	1	4.5e-10	3.6e-12	1.3e-03	78	IST1
57	16	87834943	90172696	55	35	0.0e+00	0.0e+00	NaN	NaN	ACSF3 APRT C16orf7 CBFA2T3 CHMP1A CPNE7 CTU2 CYBA DBNDD1 GALNS MC1R MGC23284 PIEZO1 RP11-46C24.7 RP11-830F9.5 RPL13 SPG7 TRAPPC2L VPS9D1 ZFPM1 ZNF276 ZNF778
58	17	45483229	46899254	1	1	1.4e-09	4.3e-06	8.6e-01	100	SNX11
59	17	78810687	80357420	7	5	4.3e-12	1.7e-21	NaN	NaN	C17orf70 MRPL12 NPLOC4 TSPAN10
60	20	21245244	21734758	1	1	2.1e-08	2.4e-07	1.0e+00	100	NKX2-2
61	20	24738226	25451180	2	1	3.2e-11	4.8e-18	2.8e-10	47	ENTPD6
62	20	29833609	36642760	72	54	0.0e+00	0.0e+00	NaN	NaN	C20orf132 C20orf160 C20orf203 C20orf24 CBFA2T2 CEP250 CHMP4B COMMD7 DLGAP4 DNMT3B EDEM2 ITCH KIF3B MANBAL MAP1LC3A MAPRE1 MMP24 NCOA6 NDRG3 PLUNC RBL1 RP4-614O4.12 RP5-1085F17.3 RPL36P4 RPN2 SOGA1 TM9SF4 TP53INP2 TSPY26P UQCC ZNF341
63	21	43194459	43693693	1	1	1.2e-07	2.8e-11	5.2e-05	63	C21orf121
64	22	37337772	40479448	7	3	1.6e-12	5.2e-13	8.5e-01	100	MAFF SH3BP1 SYNGR1
65	22	44835936	46334133	5	4	2.5e-36	1.8e-65	1.7e-21	69	C22orf9 CTA-217C2.1 LOC100506714 NUP50

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.13	2	0	0.0	0.00	1.0e+00	FNDC4 RP5-966M1.6
Bipolar Disorder or Schizophrenia	1.15	4	2	4.4	0.36	6.4e-01	CPNE7 EDEM2 ERCC8 RP5-966M1.6
Depressed Affect (Nagel 2018)	0.86	1	1	2.2	0.00	1.0e+00	PSMC3
Intelligence (Savage-Jansen 2018)	0.94	4	3	6.7	0.30	7.0e-01	CEP250 IST1 LINC01024 RP5-966M1.6
Neuroticism (Nagel 2018)	1.12	7	3	6.7	-0.81	1.4e-02	CADM2 CBFA2T3 CTU2 NCOA6 PSMC3 RP11-830F9.5 TP53INP2
Schizophrenia (2018)	1.18	3	1	2.2	0.00	1.0e+00	CPNE7 ERCC8 RP5-966M1.6
Schizophrenia vs Biploar Disorder	1.03	1	0	0.0	0.00	1.0e+00	SRPK2
Worry (Nagel 2018)	1.38	7	2	4.4	-0.50	2.6e-01	CADM2 NCOA6 PSMC3 RP4-614O4.12 RP5-966M1.6 TP53INP2 TRPS1
Crohns Disease (2017)	1.14	2	1	2.2	0.00	1.0e+00	FNDC4 MTX1P1
Irritable Bowel Disease (IBD)	1.30	8	2	4.4	-0.32	4.4e-01	ARNT CTSS FNDC4 HORMAD1 KIF3B MTX1P1 RP11-316M1.12 TM9SF4
Reaction Time	1.13	2	0	0.0	0.00	1.0e+00	COMMD7 SILV
Verbal and Numeric Reasoning (VNR)	0.99	2	1	2.2	0.00	1.0e+00	LINC01024 RP5-966M1.6
Breast Cancer	1.37	5	4	8.9	0.84	2.6e-03	CYBRD1 LINC00886 MAFF MTX1P1 RP11-554A11.9
Prostate Cancer	2.86	3	2	4.4	-0.80	5.6e-02	COMMD7 EHBP1 RP11-554A11.9
Bipolar Disorder (2011)	1.38	1	0	0.0	0.00	1.0e+00	RP5-966M1.6
Body Mass Index (BMI) (2010)	1.08	1	0	0.0	0.00	1.0e+00	PSMC3
Coronary Artery Disease (CAD)	1.23	2	0	0.0	0.00	1.0e+00	CTSS SPG7
Crohns Disease (2012)	1.10	1	0	0.0	0.00	1.0e+00	MTX1P1
Fasting Glucose	1.14	1	1	2.2	0.00	1.0e+00	FNDC4
HDL Cholesterol	1.17	1	0	0.0	0.00	1.0e+00	TRPS1
LDL Cholesterol	1.00	3	0	0.0	0.00	1.0e+00	ATG4C PARP10 RPL36P4
Neuroticism (2016)	1.07	1	0	0.0	0.00	1.0e+00	PSMC3
Primary Biliary Cirrhosis	1.14	1	1	2.2	0.00	1.0e+00	SYNGR1
Rheumatoid Arthritis	1.03	1	1	2.2	0.00	1.0e+00	SYNGR1
Schizophrenia (2014)	1.18	5	2	4.4	0.61	2.8e-01	CPNE7 ERCC8 NDUFAF2 RP5-966M1.6 TRPS1
Triglycerides	2.75	6	2	4.4	0.10	8.5e-01	ATG4C FNDC4 MAFF NCOA6 NRBF2 TP53INP2
Type 2 Diabetes (T2D) (2012)	1.51	2	1	2.2	0.00	1.0e+00	JAZF1 RAB38
Blood Eosinophil Count	1.05	22	13	28.9	0.37	6.1e-02	ANXA9 ARNT COMMD7 CORO7 CTSC CTSS EXOC2 FAM82A1 HORMAD1 JAZF1 MAPK13 RP11-316M1.12 RP5-966M1.6 RPL13 SILV SOGA1 SOX6 SPG7 ST3GAL6-AS1 TMED8 TSPY26P ZBTB7B
Blood Platelet Count	1.32	32	19	42.2	0.05	7.5e-01	ARNT C20orf203 CBFA2T2 CBFA2T3 CEP250 CORO7 CTSS CTU2 FNDC4 GALNS HORMAD1 KIF3B LEPR MAPRE1 MED20 MTX1P1 NRBF2 PARP10 PIEZO1 PSMC3 RBBP5 RP11-316M1.12 RP11-554A11.9 RP5-966M1.6 RPL13 RPL36P4 SPG7 SYNGR1 TRAM2 VPS9D1 ZBTB7B ZFPM1
Blood Red Count	0.83	32	22	48.9	-0.02	9.3e-01	C20orf203 CBFA2T2 CBFA2T3 CYBA ENTPD6 F10 FNDC4 GALNS MAFF MAP1LC3A MC1R MED20 MRPL12 NCOA6 OBFC2B PARP10 PPP2R5A PSMC3 RBBP5 RP11-830F9.5 RP4-614O4.12 RP5-1085F17.3 RP5-966M1.6 SH3BP1 TM9SF4 TMTC3 TRAPPC2L TRPS1 TSPY26P VPS9D1 ZBTB7B ZNF276
Blood White Count	0.89	16	11	24.4	0.12	6.4e-01	ARNT CORO7 CYBA FNDC4 LEPR MAP1LC3A NRBF2 PDE4B PSMC3 RBBP5 RP11-554A11.9 SRPK2 TMED8 TMTC3 TPCN2 VPS9D1
Heel T-Score	1.80	31	18	40.0	-0.22	1.6e-01	ACSF3 ANXA9 ARNT BNC2 C16orf7 C17orf70 CORO7 CTSS CTU2 EDEM2 EPM2A HORMAD1 LEKR1 LINC00886 LOC100287227 MAP1LC3A METTL15P1 MRPL12 NPLOC4 RP11-554A11.9 RP4-614O4.12 SGIP1 SH3BP1 SILV SOX6 SPG7 SSR3 TPCN2 TRPS1 TSPAN10 USP35
BMI	1.24	20	12	26.7	0.22	3.0e-01	CADM2 CPNE7 DNAJC27 F10 FNDC4 ITCH JAZF1 MANBAL MAP1LC3A MED20 NRBF2 PDE4B POMC PSMC3 RP5-966M1.6 SH3BP1 SNX11 TRPS1 TSPY26P ZBTB7B
Height	2.44	80	64	142.2	0.34	5.7e-04	ACSF3 AHR ANXA9 ARNT ATG4C ATL2 BNC2 C16orf7 C20orf132 C20orf24 CBFA2T2 CBFA2T3 CEP250 CHMP1A CHMP4B CNTLN COMMD7 CTSS CTU2 CYBA DBNDD1 DNAJC27 EPM2A ERLIN1 EXOC2 FAM46A FAM82A1 FNDC4 GDI2 IST1 ITCH JAZF1 LINC00886 MAFF MANBAL MAP1LC3A MAPK13 MAPRE1 MED20 MGC23284 MMP24 NCOA6 NDRG3 NKX2-2 NOX4 OBFC2B PARP10 PIEZO1 PLUNC POMC PPP2R5A PRELID1 PSMC3 RMDN2 RP11-305K5.1 RP11-532F6.3 RP11-830F9.5 RP4-614O4.12 RP5-966M1.6 RPL13 RPL36P4 RPN2 SH3BP1 SNX11 SOX6 SPG7 SRPK2 ST3GAL6-AS1 TP53INP2 TPCN2 TRIP11 TRPS1 UBC UQCC USP35 VPS9D1 ZBTB7B ZFPM1 ZNF341 ZNF778
Waist Hip Ratio (WHR)	1.12	9	7	15.6	0.10	8.0e-01	CORO7 CYBRD1 JAZF1 NKX2-2 PPP2R5A RP11-554A11.9 RP5-966M1.6 UQCC ZBTB7B
Systolic Blood Pressure	1.19	12	8	17.8	0.36	1.8e-01	CADM2 CEP250 COMMD7 CORO7 DNAJC27 DNMT3B FNDC4 NRBF2 PSMC3 SNX11 UQCC ZNF276
Smoking Status	1.22	4	2	4.4	1.00	3.9e-03	CADM2 LEPR PDE4B RP5-966M1.6
Allergy or Eczema	0.97	2	1	2.2	0.00	1.0e+00	JAZF1 ZBTB7B
Cardiovascular Disease	1.03	6	4	8.9	0.09	8.6e-01	FNDC4 NRBF2 PRELID1 PSMC3 TM9SF4 TSPY26P
Hypothyroidism (self reported)	1.11	2	0	0.0	0.00	1.0e+00	EXOC2 SYNGR1
Type 2 Diabetes (T2D) (2018)	1.61	6	4	8.9	0.94	1.5e-03	CBFA2T2 CHMP4B ERLIN1 FNDC4 JAZF1 RP5-1042I8.7
Lung FEV1/FVC ratio	1.43	20	12	26.7	0.02	9.3e-01	C20orf203 C20orf24 CORO7 CYBRD1 EXOC2 ITCH LINC00886 MAP1LC3A MAPRE1 NRBF2 RBBP5 RP11-305K5.1 RP11-532F6.3 RP5-1085F17.3 RP5-966M1.6 SILV SNX11 TSPY26P USP35 ZBTB7B
Lung FVC	1.69	19	12	26.7	-0.30	1.7e-01	ANXA9 ARNT CEP250 CORO7 CPNE7 CTSS EHBP1 HORMAD1 JAZF1 MAP1LC3A MAPK13 NCOA6 NRBF2 PIEZO1 RP11-316M1.12 RP4-614O4.12 RPL36P4 TP53INP2 UQCC
Neuroticism	1.22	7	2	4.4	-0.80	3.2e-02	CADM2 CBFA2T3 NCOA6 PSMC3 RP11-830F9.5 TP53INP2 USP35
Chronotype (morning person)	1.07	5	3	6.7	-0.56	3.3e-01	ANXA9 CTSS HORMAD1 RP11-316M1.12 TRPS1
Hair Pigment	26.82	88	80	177.8	-0.84	3.4e-41	ACSF3 AMACR AP3M2 APRT BNC2 C16orf7 C17orf70 C20orf132 C20orf160 C20orf203 C20orf24 C9orf150 C9orf72 CBFA2T2 CBFA2T3 CEP250 CHMP1A CHMP4B CNTLN COMMD7 CPNE7 CTSC CTU2 CYBA DBNDD1 DCT DLGAP4 DNMT3B EDEM2 ENTPD6 EXOC2 FNDC4 GALNS HERC2 IGHMBP2 ITCH JAZF1 LEKR1 LOC100287227 LURAP1L MANBAL MAP1LC3A MAPRE1 MC1R MGC23284 MMP24 MPDZ MRPL12 MTX1P1 NAALAD2 NCOA6 NDRG3 NPLOC4 OCA2 PIEZO1 PLUNC RBBP5 RBL1 RP11-46C24.7 RP11-532F6.3 RP11-54A4.2 RP11-554A11.9 RP11-830F9.5 RP4-614O4.12 RP5-1085F17.3 RPL13 RPL36P4 RXFP3 SNX11 SOGA1 SOX6 SYNGR1 TMTC3 TP53INP2 TPCN2 TRAPPC2L TRIP11 TSPAN10 TSPY26P TYRP1 UQCC USP35 VPS9D1 ZBTB7B ZFPM1 ZNF276 ZNF341 ZNF778
Hand grip strength (left)	1.52	7	5	11.1	0.59	9.5e-02	CADM2 CEP250 MAP1LC3A PSMC3 RP4-614O4.12 SNX11 UQCC
Number of treatments/medications taken	1.28	3	0	0.0	0.00	1.0e+00	ACSF3 COMMD7 FNDC4
Relative age of first facial hair	1.81	5	4	8.9	-0.99	1.2e-04	DBNDD1 FNDC4 HERC2 MC1R TSPAN10
Systolic blood pressure, automated reading	0.92	3	3	6.7	0.00	1.0e+00	NRBF2 PSMC3 SNX11
Vitamin and mineral supplements	1.09	1	0	0.0	0.00	1.0e+00	ITCH
Medication: Metformin	1.25	3	2	4.4	0.00	1.0e+00	FNDC4 JAZF1 PSMC3
Diabetes (father)	1.16	1	0	0.0	0.00	1.0e+00	FNDC4
Impedance of leg (right)	1.88	25	13	28.9	-0.42	1.9e-02	ARNT CADM2 CEP250 CTSS CYBA CYBRD1 FNDC4 IGHMBP2 JAZF1 LOC100506714 MANBAL MAPRE1 MED20 NCOA6 PPP2R5A PRELID1 RP11-316M1.12 RP11-54A4.2 RP5-966M1.6 RPL36P4 SOX6 TP53INP2 TRPS1 UQCC ZBTB7B
Leg fat-free mass (left)	2.43	33	21	46.7	0.45	5.1e-03	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC ZBTB7B
Trunk fat percentage	1.12	11	7	15.6	0.19	5.6e-01	CPNE7 DBNDD1 DNAJC27 MAFF MAPK13 PDE4B POMC PSMC3 RP11-316M1.12 SNX11 TRPS1
Hand grip strength (right)	1.62	10	4	8.9	0.59	4.5e-02	CADM2 CEP250 MAP1LC3A MAPRE1 METTL15P1 PSMC3 RP11-54A4.2 RP4-614O4.12 SPG7 UQCC
Fed-up feelings	0.93	1	0	0.0	0.00	1.0e+00	PSMC3
Relative age voice broke	1.36	1	0	0.0	0.00	1.0e+00	UQCC
Taking other prescription medications	1.21	1	0	0.0	0.00	1.0e+00	TM9SF4
Age when periods started (menarche)	0.96	3	1	2.2	0.00	1.0e+00	LEPR RP5-966M1.6 USP35
Heel bone mineral density (BMD) T-score, automated (left)	1.57	4	3	6.7	-0.66	7.3e-02	EDEM2 LEKR1 LINC00886 TPCN2
High blood pressure	0.97	3	3	6.7	0.00	1.0e+00	NRBF2 PSMC3 TSPY26P
Hayfever, allergic rhinitis or eczema	0.91	1	0	0.0	0.00	1.0e+00	ZBTB7B
Supplements: Glucosamine	1.05	1	1	2.2	0.00	1.0e+00	NRBF2
Sitting height	2.68	38	24	53.3	0.46	2.3e-03	C20orf24 CBFA2T2 CEP250 COMMD7 CORO7 CTU2 CYBA DBNDD1 DNAJC27 FAM46A FNDC4 ITCH JAZF1 KIF3B MAFF MAP1LC3A MED20 MMP24 NCOA6 NDRG3 NKX2-2 OBFC2B PARP10 POMC PPP2R5A PSMC3 RP11-830F9.5 RP4-614O4.12 RP5-966M1.6 RPL13 RPL36P4 SH3BP1 SPG7 ST3GAL6-AS1 TP53INP2 TRPS1 UQCC ZBTB7B
Body mass index (BMI)	1.10	11	7	15.6	-0.34	3.1e-01	CADM2 DNAJC27 FNDC4 JAZF1 MED20 PDE4B POMC PSMC3 RP5-966M1.6 TRPS1 ZBTB7B
Impedance of leg (left)	1.85	26	11	24.4	-0.41	2.3e-02	ARNT CADM2 CEP250 CYBA CYBRD1 FNDC4 IGHMBP2 ITCH JAZF1 LOC100506714 MANBAL MED20 NCOA6 PPP2R5A PRELID1 RP11-316M1.12 RP11-54A4.2 RP5-966M1.6 RPL13 RPL36P4 SOX6 SPG7 TP53INP2 TRPS1 UQCC ZBTB7B
Leg predicted mass (left)	2.43	33	21	46.7	0.45	5.0e-03	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC ZBTB7B
Trunk fat mass	1.29	15	9	20.0	0.36	1.5e-01	CADM2 CEP250 DBNDD1 EHBP1 MAFF MAP1LC3A MAPK13 MED20 NDRG3 PDE4B POMC PSMC3 SNX11 TRPS1 UQCC
Waist circumference	1.22	10	4	8.9	0.02	9.5e-01	CADM2 EHBP1 MED20 NDRG3 PDE4B POMC PSMC3 RPL13 SNX11 TRPS1
Past tobacco smoking	1.37	3	1	2.2	0.00	1.0e+00	CADM2 MAP1LC3A PDE4B
Alcohol usually taken with meals	1.34	1	0	0.0	0.00	1.0e+00	CEP250
Nervous feelings	1.31	5	2	4.4	-0.59	2.9e-01	CADM2 NCOA6 RP5-966M1.6 TP53INP2 TRPS1
Hearing difficulty/problems with background noise	0.97	1	0	0.0	0.00	1.0e+00	PRELID1
Hair/balding pattern: Pattern 2	1.67	2	2	4.4	-0.22	7.8e-01	COMMD7 DNMT3B
Had menopause	1.19	2	0	0.0	0.00	1.0e+00	C16orf7 ZNF276
Forced vital capacity (FVC)	1.35	13	7	15.6	0.55	4.2e-02	ANXA9 ARNT CBFA2T2 COMMD7 CTSS HORMAD1 IST1 MAPK13 NOX4 OBFC2B PRELID1 RP11-316M1.12 UQCC
Heel bone mineral density (BMD) T-score, automated (right)	1.50	5	3	6.7	-0.71	2.1e-02	EDEM2 EPM2A LEKR1 LINC00886 TPCN2
Qualifications: None of the above	0.84	1	0	0.0	0.00	1.0e+00	IST1
Allergy	0.99	2	0	0.0	0.00	1.0e+00	JAZF1 MAPRE1
Diabetes (self-reported)	1.74	3	3	6.7	0.00	1.0e+00	FNDC4 JAZF1 RP5-1042I8.7
Medication: Simvastatin	0.84	1	1	2.2	0.00	1.0e+00	FNDC4
Neuroticism score	1.08	5	3	6.7	-0.81	9.7e-02	CBFA2T3 NCOA6 PSMC3 RP11-830F9.5 TP53INP2
Weight	1.88	30	19	42.2	0.43	1.2e-02	CADM2 CBFA2T2 CEP250 CTU2 DBNDD1 EHBP1 FNDC4 ITCH MAFF MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NOX4 PARP10 PDE4B POMC PRELID1 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRPS1 TYRP1 UQCC ZBTB7B
Impedance of arm (right)	1.81	26	15	33.3	-0.14	4.4e-01	ARNT CADM2 CEP250 DBNDD1 FNDC4 HORMAD1 IGHMBP2 JAZF1 LINC00886 MAFF MANBAL MAP1LC3A MED20 NCOA6 NRBF2 PPP2R5A PRELID1 RP11-316M1.12 RP11-54A4.2 RP5-966M1.6 RPL36P4 TP53INP2 TSPY26P UQCC USP35 ZBTB7B
Arm fat percentage (right)	1.00	8	7	15.6	-0.14	7.3e-01	CPNE7 DNAJC27 MAFF MAPK13 PDE4B POMC PSMC3 TRPS1
Trunk fat-free mass	2.79	38	27	60.0	0.37	1.4e-02	C20orf24 CADM2 CBFA2T2 CEP250 CORO7 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NKX2-2 NOX4 OBFC2B PARP10 PIEZO1 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC VPS9D1 ZBTB7B
Hip circumference	1.53	23	14	31.1	0.39	5.9e-02	CADM2 CBFA2T2 CEP250 DBNDD1 DNAJC27 EHBP1 FNDC4 ITCH MAFF MAP1LC3A MED20 NDRG3 NOX4 PDE4B POMC PSMC3 RPL36P4 SNX11 TP53INP2 TPCN2 TRPS1 UQCC ZBTB7B
Alcohol intake versus 10 years previously	1.49	2	1	2.2	0.00	1.0e+00	CTSC FNDC4
Worrier / anxious feelings	1.18	2	2	4.4	0.00	1.0e+00	CADM2 RP5-966M1.6
Frequency of tiredness / lethargy in last 2 weeks	1.03	1	0	0.0	0.00	1.0e+00	CBFA2T3
Number of live births	1.01	2	0	0.0	0.00	1.0e+00	CADM2 DBNDD1
Forced expiratory volume in 1-second (FEV1)	1.39	10	4	8.9	0.71	2.1e-02	ANXA9 ARNT CBFA2T2 CTSS MAPK13 NOX4 NRBF2 RP11-316M1.12 TPCN2 UQCC
Pulse rate	1.21	1	1	2.2	0.00	1.0e+00	FNDC4
Qualifications: A levels/AS levels or equivalent	0.81	2	0	0.0	0.00	1.0e+00	SRPK2 UQCC
Mouth/teeth dental problems: Dentures	1.25	1	0	0.0	0.00	1.0e+00	SNX11
Asthma	1.11	1	0	0.0	0.00	1.0e+00	TRAPPC2L
Medication: Cholesterol lowering	1.21	1	1	2.2	0.00	1.0e+00	FNDC4
Lung cancer (father)	1.12	1	0	0.0	0.00	1.0e+00	CHMP4B
Forced expiratory volume in 1-second (FEV1), Best measure	1.30	10	5	11.1	0.66	2.8e-02	ANXA9 ARNT CBFA2T2 CBFA2T3 CTSS MAPK13 NRBF2 OBFC2B RP11-316M1.12 UQCC
Impedance of arm (left)	1.73	28	11	24.4	-0.13	5.1e-01	ARNT CADM2 CBFA2T2 CEP250 DBNDD1 FNDC4 HORMAD1 IGHMBP2 ITCH JAZF1 LINC00886 MAFF MANBAL MAP1LC3A MED20 NCOA6 NKX2-2 NRBF2 PPP2R5A PRELID1 RP11-316M1.12 RP11-54A4.2 RP5-966M1.6 RPL36P4 TP53INP2 UQCC USP35 ZBTB7B
Arm fat mass (right)	1.21	18	9	20.0	0.30	2.3e-01	CADM2 CPNE7 DNAJC27 EHBP1 FNDC4 ITCH MAFF MAP1LC3A MED20 NDRG3 PDE4B POMC PSMC3 RPL13 SNX11 TRPS1 UQCC ZBTB7B
Trunk predicted mass	2.79	37	26	57.8	0.37	1.5e-02	C20orf24 CADM2 CBFA2T2 CEP250 CORO7 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NKX2-2 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC VPS9D1 ZBTB7B
Standing height	2.40	49	39	86.7	0.38	3.2e-03	C16orf7 C20orf24 CBFA2T2 CBFA2T3 CEP250 CHMP1A COMMD7 CORO7 CTU2 DBNDD1 DNAJC27 EPM2A ERLIN1 FAM46A FNDC4 ITCH JAZF1 LINC00886 MAFF MANBAL MAP1LC3A MED20 MMP24 NCOA6 NDRG3 NOX4 OBFC2B PARP10 PIEZO1 PLUNC POMC PPP2R5A PRELID1 PSMC3 RP11-830F9.5 RP4-614O4.12 RP5-966M1.6 RPL13 RPL36P4 SH3BP1 SNX11 SPG7 TP53INP2 TPCN2 TRIP11 TRPS1 UQCC VPS9D1 ZBTB7B
Tense / 'highly strung'	1.06	3	0	0.0	0.00	1.0e+00	CADM2 NCOA6 TP53INP2
Hair/balding pattern: Pattern 4	1.08	7	2	4.4	-0.45	3.1e-01	COMMD7 DBNDD1 EXOC2 MAP1LC3A MAPRE1 RP4-614O4.12 TRPS1
Birth weight of first child	1.12	2	1	2.2	0.00	1.0e+00	MAPK13 SSR3
Peak expiratory flow (PEF)	1.53	5	3	6.7	0.76	4.8e-02	CEP250 MAP1LC3A TPCN2 TRPS1 UQCC
Blood clot in the leg (DVT)	1.17	1	0	0.0	0.00	1.0e+00	NCOA6
Medication: Paracetamol	1.05	1	0	0.0	0.00	1.0e+00	TMTC3
Headache pain in last month	1.03	3	0	0.0	0.00	1.0e+00	KIF3B RP11-54A4.2 RP5-966M1.6
Medication for cholesterol, blood pressure or diabetes	1.00	3	1	2.2	0.00	1.0e+00	CHMP4B FNDC4 TSPY26P
Gout (self-reported)	1.29	1	1	2.2	0.00	1.0e+00	FNDC4
Hypothyroidism/myxoedema (self-reported)	1.06	2	0	0.0	0.00	1.0e+00	EXOC2 SYNGR1
Birth weight	1.25	4	1	2.2	-0.90	1.0e-01	COMMD7 MAPK13 MAPRE1 ZBTB7B
High blood pressure (siblings)	1.15	1	1	2.2	0.00	1.0e+00	NRBF2
Forced vital capacity (FVC), Best measure	1.40	13	9	20.0	0.58	2.4e-02	ANXA9 ARNT CBFA2T2 COMMD7 CTSS HORMAD1 IST1 MAPK13 NOX4 OBFC2B PRELID1 RP11-316M1.12 UQCC
Body fat percentage	1.05	11	7	15.6	0.07	8.4e-01	ARNT CPNE7 DBNDD1 DNAJC27 MAFF MAPK13 PDE4B POMC PSMC3 RP11-316M1.12 TRPS1
Leg fat percentage (right)	1.09	11	7	15.6	-0.31	3.5e-01	C17orf70 CADM2 DNAJC27 MAFF MAPK13 PDE4B POMC PSMC3 TRPS1 TSPAN10 UQCC
Arm fat-free mass (right)	2.62	30	22	48.9	0.39	2.4e-02	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBRD1 FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SNX11 SPG7 TP53INP2 TRPS1 TYRP1 UQCC VPS9D1 ZBTB7B
Comparative body size at age 10	1.46	6	3	6.7	-0.05	9.3e-01	CADM2 DNAJC27 LEPR POMC PSMC3 TP53INP2
Worry too long after embarrassment	1.41	5	1	2.2	-0.78	6.9e-02	DBNDD1 NCOA6 NKX2-2 RP11-830F9.5 TP53INP2
Number of children fathered	1.21	1	1	2.2	0.00	1.0e+00	CADM2
Qualifications: College or University degree	0.89	2	1	2.2	0.00	1.0e+00	CADM2 IST1
Mouth/teeth dental problems: Loose teeth	1.18	1	0	0.0	0.00	1.0e+00	DNAJC27
Neck or shoulder pain in last month	1.36	1	0	0.0	0.00	1.0e+00	COMMD7
Medication: Blood pressure	1.18	2	1	2.2	0.00	1.0e+00	PSMC3 TSPY26P
Medication: Allopurinol	1.22	2	1	2.2	0.00	1.0e+00	FNDC4 ZBTB7B
Mean time to correctly identify matches	1.00	1	0	0.0	0.00	1.0e+00	SRPK2
Whole body fat mass	1.21	16	7	15.6	0.30	2.5e-01	CADM2 DBNDD1 DNAJC27 EHBP1 ITCH MAFF MAP1LC3A MAPK13 MED20 NDRG3 PDE4B POMC PSMC3 SNX11 TRPS1 UQCC
Leg fat mass (right)	1.17	9	6	13.3	0.14	7.2e-01	CADM2 DNAJC27 MAFF MAP1LC3A PDE4B POMC PSMC3 TRPS1 TSPY26P
Arm predicted mass (right)	2.60	29	21	46.7	0.49	3.5e-03	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBRD1 FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRPS1 TYRP1 UQCC ZBTB7B
Pulse rate, automated reading	1.24	5	2	4.4	-0.69	8.4e-02	CNTLN FNDC4 LEKR1 SGIP1 USP35
Alcohol intake frequency.	1.27	4	4	8.9	-0.57	4.3e-01	CADM2 FNDC4 IST1 PSMC3
Comparative height size at age 10	2.22	38	24	53.3	0.31	4.7e-02	C16orf7 C20orf132 C20orf24 CBFA2T2 CEP250 COMMD7 CTU2 DNAJC27 FAM46A FNDC4 ITCH JAZF1 MAFF MANBAL MAP1LC3A MAPRE1 NCOA6 NDRG3 NOX4 PARP10 PDE4B PIEZO1 POMC PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SNX11 SPG7 ST3GAL6-AS1 TMED8 TP53INP2 TRIP11 TRPS1 UQCC VPS9D1 ZBTB7B
Number of full sisters	1.13	2	0	0.0	0.00	1.0e+00	CADM2 NRBF2
Suffer from 'nerves'	0.96	2	2	4.4	0.00	1.0e+00	CADM2 PSMC3
Overall health rating	1.16	3	0	0.0	0.00	1.0e+00	NDRG3 TM9SF4 TSPY26P
Knee pain experienced in last month	1.66	3	2	4.4	-0.98	2.1e-02	CEP250 RPL36P4 UQCC
Hypertension (Self-reported)	0.95	3	3	6.7	0.00	1.0e+00	NRBF2 PSMC3 TSPY26P
Smoking status: Previous	1.28	1	1	2.2	0.00	1.0e+00	CADM2
Forced expiratory volume in 1-second (FEV1), predicted	1.77	10	4	8.9	0.71	1.4e-02	CBFA2T2 CEP250 DBNDD1 JAZF1 MAP1LC3A MMP24 NCOA6 OBFC2B TP53INP2 UQCC
Whole body fat-free mass	2.69	35	23	51.1	0.46	2.8e-03	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NKX2-2 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC ZBTB7B
Leg fat-free mass (right)	2.51	33	22	48.9	0.46	3.9e-03	C20orf24 CADM2 CBFA2T2 CEP250 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH MANBAL MAP1LC3A MAPRE1 MED20 NCOA6 NDRG3 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC ZBTB7B
Arm fat percentage (left)	1.02	8	6	13.3	-0.17	6.8e-01	CPNE7 DNAJC27 MAFF MAPK13 PDE4B POMC PSMC3 TRPS1
Mood swings	0.95	2	1	2.2	0.00	1.0e+00	CBFA2T3 PSMC3
Loneliness, isolation	0.97	1	1	2.2	0.00	1.0e+00	PSMC3
Long-standing illness, disability or infirmity	1.24	2	0	0.0	0.00	1.0e+00	COMMD7 TM9SF4
Diabetes diagnosed by doctor	1.65	4	3	6.7	0.99	6.7e-03	CHMP4B FNDC4 JAZF1 RP5-1042I8.7
Mouth/teeth dental problems: Mouth ulcers	1.27	5	1	2.2	0.99	9.4e-05	ANXA9 ARNT CTSS HORMAD1 RP11-316M1.12
Medication for cholesterol	1.01	2	1	2.2	0.00	1.0e+00	FNDC4 ZNF276
Back pain experienced in last month	1.49	1	0	0.0	0.00	1.0e+00	ZNF778
Mineral and other dietary supplements	1.05	1	0	0.0	0.00	1.0e+00	NRBF2
Breast cancer (self-reported)	0.87	1	1	2.2	0.00	1.0e+00	CYBRD1
Asthma (self-reported)	1.10	1	0	0.0	0.00	1.0e+00	TRAPPC2L
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.12	3	0	0.0	0.00	1.0e+00	LINC01024 NRBF2 UQCC
Whole body water mass	2.70	36	24	53.3	0.46	2.7e-03	C20orf24 CADM2 CBFA2T2 CEP250 CORO7 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NKX2-2 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC ZBTB7B
Leg predicted mass (right)	2.52	32	22	48.9	0.47	3.2e-03	C20orf24 CADM2 CBFA2T2 CEP250 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH MANBAL MAP1LC3A MAPRE1 MED20 NCOA6 NDRG3 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 UQCC ZBTB7B
Arm fat mass (left)	1.23	15	10	22.2	0.23	4.1e-01	CADM2 DNAJC27 EHBP1 FNDC4 ITCH MAFF MAP1LC3A MED20 NDRG3 PDE4B POMC PSMC3 TRPS1 UQCC ZBTB7B
Number of self-reported non-cancer illnesses	1.17	1	1	2.2	0.00	1.0e+00	FNDC4
Miserableness	0.92	1	1	2.2	0.00	1.0e+00	PSMC3
Guilty feelings	1.08	1	1	2.2	0.00	1.0e+00	PSMC3
Medication: Blood pressure	1.14	2	0	0.0	0.00	1.0e+00	CPNE7 NRBF2
High cholesterol (Self-reported)	1.25	1	1	2.2	0.00	1.0e+00	FNDC4
Medication: Lisinopril	1.23	1	0	0.0	0.00	1.0e+00	NRBF2
Medication: Atorvastatin	1.22	1	1	2.2	0.00	1.0e+00	FNDC4
Illnesses of father: High blood pressure	1.15	1	0	0.0	0.00	1.0e+00	PSMC3
Ever smoked	1.20	2	2	4.4	0.00	1.0e+00	CADM2 PDE4B
Basal metabolic rate	2.53	34	24	53.3	0.46	2.9e-03	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBA CYBRD1 FAM46A FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NOX4 OBFC2B PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC ZBTB7B
Leg fat percentage (left)	1.02	9	6	13.3	-0.44	2.4e-01	CADM2 DNAJC27 MAFF MAPK13 PDE4B POMC PSMC3 TRPS1 UQCC
Arm fat-free mass (left)	2.55	35	23	51.1	0.37	2.0e-02	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBA CYBRD1 EHBP1 FNDC4 IGHMBP2 ITCH JAZF1 MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NKX2-2 PARP10 PIEZO1 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC VPS9D1 ZBTB7B
Irritability	1.29	4	2	4.4	-0.97	2.8e-02	CBFA2T3 NCOA6 RP11-830F9.5 TP53INP2
Risk taking	1.17	1	1	2.2	0.00	1.0e+00	CADM2
Fractured/broken bones in last 5 years	1.08	1	0	0.0	0.00	1.0e+00	TPCN2
Diastolic blood pressure, automated reading	0.84	3	2	4.4	0.00	1.0e+00	DLGAP4 NRBF2 PSMC3
Vascular/heart problems diagnosed by doctor	0.98	3	3	6.7	0.00	1.0e+00	NRBF2 PSMC3 TSPY26P
Cholesterol lowering medication	0.95	1	1	2.2	0.00	1.0e+00	FNDC4
Pain experienced in last month	1.52	5	1	2.2	0.66	1.5e-01	CBFA2T3 COMMD7 KIF3B TM9SF4 TRAPPC2L
Basal cell carcinoma (self-reported)	2.69	4	2	4.4	-0.99	1.5e-03	DBNDD1 NCOA6 RP4-614O4.12 TP53INP2
Deep venous thrombosis (DVT) (self-reported)	1.19	1	0	0.0	0.00	1.0e+00	NCOA6
Impedance of whole body	1.88	27	17	37.8	-0.19	2.8e-01	ARNT CADM2 CBFA2T2 CEP250 DBNDD1 FNDC4 HORMAD1 IGHMBP2 ITCH JAZF1 MAFF MANBAL MAP1LC3A MED20 NCOA6 PPP2R5A PRELID1 RP11-316M1.12 RP11-54A4.2 RP5-966M1.6 RPL36P4 SOX6 SPG7 TP53INP2 UQCC USP35 ZBTB7B
Leg fat mass (left)	1.17	11	6	13.3	0.00	1.0e+00	CADM2 DNAJC27 EHBP1 FNDC4 MAFF MAP1LC3A PDE4B POMC PSMC3 TRPS1 ZBTB7B
Arm predicted mass (left)	2.57	33	22	48.9	0.37	2.2e-02	C20orf24 CADM2 CBFA2T2 CEP250 CTU2 CYBA CYBRD1 EHBP1 FNDC4 IGHMBP2 ITCH MANBAL MAP1LC3A MED20 NCOA6 NDRG3 NKX2-2 PARP10 PRELID1 RP4-614O4.12 RPL13 RPL36P4 RPN2 SILV SNX11 SPG7 TP53INP2 TRIP11 TRPS1 TYRP1 UQCC VPS9D1 ZBTB7B

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	45	1.29	16.9
GTEx	Adipose Visceral Omentum	22	1.08	9.0
GTEx	Adrenal Gland	28	1.92	29.4
GTEx	Artery Aorta	40	1.34	15.1
GTEx	Artery Coronary	10	0.84	17.6
GTEx	Artery Tibial	43	1.14	13.0
GTEx	Brain Caudate basal ganglia	13	1.41	4.1
GTEx	Brain Cerebellar Hemisphere	25	1.68	30.4
GTEx	Brain Cerebellum	30	1.51	30.6
GTEx	Brain Cortex	16	1.55	35.0
GTEx	Brain Frontal Cortex BA9	17	1.84	9.8
GTEx	Brain Hippocampus	8	1.52	5.1
GTEx	Brain Hypothalamus	10	1.69	12.8
GTEx	Brain Nucleus accumbens basal ganglia	12	1.39	6.8
GTEx	Brain Putamen basal ganglia	9	1.44	5.1
GTEx	Breast Mammary Tissue	31	1.57	9.7
GTEx	Breast Mammary Tissue (Male)	21	1.76	25.1
GTEx	Breast Mammary Tissue (Female)	29	1.76	13.5
GTEx	Cells EBV-transformed lymphocytes	23	1.62	5.8
GTEx	Cells Transformed fibroblasts	61	1.45	12.9
GTEx	Colon Sigmoid	21	1.44	27.6
GTEx	Colon Transverse	25	1.21	19.1
GTEx	Esophagus Gastroesophageal Junction	17	1.18	9.3
GTEx	Esophagus Mucosa	44	1.32	10.1
GTEx	Esophagus Muscularis	45	1.39	16.3
GTEx	Heart Atrial Appendage	23	1.46	20.6
GTEx	Heart Left Ventricle	20	1.31	19.0
GTEx	Liver	12	1.67	4.4
GTEx	Lung	38	1.32	14.8
GTEx	Muscle Skeletal	44	1.52	10.8
GTEx	Nerve Tibial	57	1.32	13.1
GTEx	Ovary	11	1.21	13.1
GTEx	Pancreas	29	1.78	19.3
GTEx	Pituitary	18	1.61	22.6
GTEx	Prostate	12	1.44	16.4
GTEx	Skin Not Sun Exposed Suprapubic	39	1.59	21.7
GTEx	Skin Sun Exposed Lower leg	55	1.51	12.8
GTEx	Small Intestine Terminal Ileum	7	1.52	24.7
GTEx	Spleen	17	1.20	15.9
GTEx	Stomach	19	1.31	33.4
GTEx	Testis	45	1.43	11.0
GTEx	Thyroid	52	1.30	15.4
GTEx	Uterus	8	1.41	11.2
GTEx	Vagina	7	1.10	6.8
GTEx	Whole Blood	33	1.66	11.1
METSIM	Adipose	54	1.17	14.3
NTR	Blood	23	0.96	4.6
ROSMAP	Brain Pre-frontal Cortex	36	0.82	3.7
YFS	Blood	41	0.89	6.2
CommonMind	Brain Pre-frontal Cortex	72	1.34	12.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	23	1.39	8.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	50	1.13	6.9
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	8	0.73	3.4
The Cancer Genome Atlas	Colon Adenocarcinoma	23	1.11	7.5
The Cancer Genome Atlas	Esophageal Carcinoma	9	1.31	4.0
The Cancer Genome Atlas	Glioblastoma Multiforme	13	1.27	3.9
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	39	1.43	13.0
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	47	1.15	10.4
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	17	0.83	10.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	46	1.07	11.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	13	1.18	5.4
The Cancer Genome Atlas	Lung Adenocarcinoma	29	0.99	8.0
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	34	1.35	5.5
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	18	1.13	4.2
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	19	1.14	10.2
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	9	0.68	6.1
The Cancer Genome Atlas	Prostate Adenocarcinoma	51	1.10	8.5
The Cancer Genome Atlas	Rectum Adenocarcinoma	5	0.72	2.5
The Cancer Genome Atlas	Soft Tissue Sarcoma	11	1.03	4.0
The Cancer Genome Atlas	Skin Cutaneous Melanoma	7	1.31	5.1
The Cancer Genome Atlas	Stomach Adenocarcinoma	24	1.42	9.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	15	1.17	5.0
The Cancer Genome Atlas	Thyroid Carcinoma	51	0.99	9.9
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	9	1.76	7.6